Liquidia Corporation

LQDA Healthcare Drug Manufacturers Specialty & Generic

Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.

Revenue
+1,842.7%
EPS
+271.4%
Free cash flow
+270.2%
Total debt
−9.04%

Quarter to June 2026, against a year earlier

44.69 2.69 −5.68%
Market cap
$4.0B
P/E
28.5×
Fwd P/E
22.1×
Dividend yield
—
F-score
5/9
Altman Z
4.08
Beneish M
6.79
Dividend safety
n/a

Liquidia Corporation (LQDA) Operating cash flow

Alert me on Operating cash flow

Liquidia Corporation's operating cash flow for fiscal 2025 was −$35.7M, compared with −$93.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $167.7M. Over the past ten years it has ranged from −$93.4M (fiscal 2024) to −$13.9M (fiscal 2016); the current reading is higher than 45% of that period. Liquidia Corporation ranks 25th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 −$35.7M —
FY2024 −$93.4M —
FY2023 −$41.6M —
FY2022 −$28.6M —
FY2021 −$34.0M —
FY2020 −$54.1M —
FY2019 −$48.3M —
FY2018 −$31.8M —
FY2017 −$24.3M —
FY2017 −$24.3M —

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $80.2M 51.43%
Mar 2026 $53.0M 19.77%
Dec 2025 $44.2M —
Sep 2025 −$9.8M —
33 more quarters

Against its own ten years

Low −$93.4M High −$13.9M
Ten-year median −$34.0M
Current reading's percentile 45

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on LQDA